Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in SSc-ILD (BUILD-2)
NCT00070590Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2003
- Primary completion
- Sep 2005
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial in interstitial lung disease (ILD) comparing Bosentan with Placebo (2 arms). Primary endpoint: Change from baseline to End-of-Study in 6-minute walk distance. Started Jul 2003; status: completed.
02
Drugs
bosentan
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT00070590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070590.